Videos

2020 was another momentous year for anti-CGRP therapies.  With the last of the CGRP monoclonal antibodies and the first gepants gaining their first approvals in the USA,1-3 and other anti-CGRP therapies gaining approvals around the world, clinicians have seen a rapid increase in the range of treatments available for their patients with migraine. New clinical …

As clinicians witness a revolution in thinking about migraine and its treatment, Peter Goadsby considers how the future availability of CGRP monoclonal antibodies and small molecule gepants will change the treatment landscape. He welcomes the growing opportunities for patients to be offered individualised treatment that enables them to take back control of their lives.  

In the third in his series of videos about the future of CGRP therapies, Peter Goadsby describes the research that led to the approval of galcanezumab for the treatment of episodic cluster headache and looks forward to better understanding of how treatment can be optimised for patients most likely to benefit.

Following the US approval of the first CGRP small molecule receptor antagonist, ubrogepant, for the acute treatment of migraine, Peter Goadsby looks at the potential impact of targeting the CGRP pathway for both prevention and treatment of migraine.

Extensive clinical trial data support the efficacy and safety of anti-CGRP therapies in patients with migraine but there is still much to be learned about their precise role in daily practice. In the first of a series of videos about what comes next for anti-CGRP therapy, Peter Goadsby discusses the challenges that still need to …

The Calcitonin Gene-Related Peptide (CGRP) Forum has been established by an international group of clinicians and researchers. It provides all healthcare professionals with open and free access to independent news, information, comment and resources about the exciting potential of CGRP as a novel therapeutic target for the prevention of migraine in millions of people worldwide.

Multiple lines of evidence support a role for CGRP in migraine pathophysiology. Its blockade is now a potentially important therapeutic target for migraine prevention.